Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) has issued an update.
TOT BIOPHARM International Co. Ltd. reported a significant financial turnaround in 2024, achieving a net profit of RMB34,757 thousand, driven by a 41% increase in revenue to over RMB1 billion. The company’s CDMO business showed strong growth potential, securing 58 new projects and enhancing its future revenue expectations, while maintaining high standards of quality management recognized globally.
More about TOT BIOPHARM International Co. Ltd.
TOT BIOPHARM International Co. Ltd. operates in the biopharmaceutical industry, focusing on the development, production, and commercialization of oncology drugs. The company offers products like Pusintin® (Bevacizumab injection) and provides Contract Development and Manufacturing Organization (CDMO) services, with a strong emphasis on quality management and compliance with international standards.
YTD Price Performance: 15.08%
Average Trading Volume: 103,306
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$1.59B
See more data about 1875 stock on TipRanks’ Stock Analysis page.